TX-TECH-MAHINDRA
Tech Mahindra Ltd., one of the fastest growing Global IT companies and a leading provider of digital transformation, consulting and business re-engineering services and solutions, today announced the launch of a first-of-its-kind phygital (physical and digital) Global Chess League. It also announced that Viswanathan Anand, five-time World Chess Champion, and Indian Chess Grandmaster will mentor, partner, advise and help shape the league. With his motivational and inspirational stature across the world as an individual and a chess champion, Anand will help catalyse the growth of chess, further building the sport that has defined his entire life as he joins hands with the Tech Mahindra Global Chess League and becomes its face for the global audience and his fans.
The League’s launch will mark a watershed moment as it aims to raise the profile of the sport, discover new generations of chess champions, enhance the fan base of the sport and take the sport to new commercial heights. New-age technologies such as 5G, artificial intelligence, and virtual reality will be at the core and will be leveraged to explore innovative ways of promoting the game through interactive platforms to engage a global audience. Tech Mahindra will act as the architect behind this concept and will provide necessary operational and technological support to execute the vision.
Anand Mahindra, Chairman, Mahindra Group, said, “Chess still has an incipient and largely untapped potential across the globe. Recently, there has been a surge of interest post the online Chess Olympiad and the enormous popularity of a TV series based on the game. We hope that the creation of a league will harness this resurgence of interest and bring about a renaissance in the world of chess. I am particularly excited about sharing my learnings from founding the Pro Kabaddi league with the team in order to replicate that success on a much larger and global platform.”
Viswanathan Anand, 5-time World Chess Champion, said , “Chess is a game that is played by millions around the world. At this time, a unique opportunity exists to popularize it further and dramatically enhance its visibility through a global league powered by technology. I am personally happy to partner with a technology provider like Tech Mahindra, whose endorsement and promotion will certainly elevate the sport to a higher level and offer the right platform to popularize chess across the globe. There is a renewed interest in the game of chess and through this unique global league format, we will be able to keep the spirit of chess intact and ensure the right platform is provided to upcoming talent.”
Current plans envision the League to engage players from all levels – professional or otherwise. The League will have 8 franchise owned teams from across the world. The teams will comprise of a mix of titled women and men players along with juniors and wildcard entrants playing each other in a Round Robin format. The teams qualifying for the semifinals will enter the knockout stage of the championship. We are actively looking at the prospect of introducing innovative scoring, board selection methods and a fantasy league to maximize viewer engagement. The final League structure and team details will be announced in due course.
CP Gurnani, MD & CEO, Tech Mahindra, said, “Chess has many synergies with the business world, with its emphasis on intellect, strategy and mental rigor. By leveraging Tech Mahindra’s expertise in new age technologies like 5G and Virtual Reality to drive fan engagement and viewership globally, we can truly transform chess into an e-sport. Furthermore, this global chess league will help us create an exceptional and inspirational experience by bringing the game home to global fans.”
As part of its NXT.NOW framework, which aims to enhance ‘Human Centric Experience’, Tech Mahindra has a deep focus on leveraging cutting-edge technologies to deliver enhanced experience and enable digital transformation to meet the evolving needs of the customer.
About Viswanathan Anand
As a five-time World Chess Champion, Viswanathan Anand has cemented his place among the greatest Champions of all times. His hallmark lightning speed and intuitive play is well recognized and critics rate him as one of the biggest natural talents ever in the history of chess. He is the only champion in chess history to have won a World championship title in all formats, match, knock-out and tournament. In India he has received the high civilian awards of Padma Vibhushan, Padma Bhushan, Padma Shri and Arjuna Award. He is also the first recipient of the Rajiv Gandhi Khel Ratna Award. He is also a six-time winner of the coveted “Chess Oscars.”
About Tech Mahindra
Tech Mahindra offers innovative and customer-centric digital experiences, enabling enterprises, associates and the society to Rise. We are a USD 5.2 billion organization with 121,900+ professionals across 90 countries helping 997 global customers, including Fortune 500 companies. We are focused on leveraging next-generation technologies including 5G, Blockchain, Cybersecurity, Artificial Intelligence, and more, to enable end-to-end digital transformation for global customers. Tech Mahindra is one of the fastest growing brands and amongst the top 15 IT service providers globally. Tech Mahindra has consistently emerged as a leader in sustainability and is recognized amongst the ‘2021 Global 100 Most sustainable corporations in the World’ by Corporate Knights. With the NXT.NOW framework, Tech Mahindra aims to enhance ‘Human Centric Experience’ for our ecosystem and drive collaborative disruption with synergies arising from a robust portfolio of companies. We aim at delivering tomorrow’s experiences today, and believe that the ‘Future is Now’.
We are part of the Mahindra Group, a USD 19.4 billion federation of companies that enables people to rise through innovative mobility solutions, driving rural prosperity, enhancing urban living, nurturing new businesses and fostering communities. It enjoys a leadership position in utility vehicles, information technology, financial services and vacation ownership in India and is the world’s largest tractor company by volume. It also enjoys a strong presence in renewable energy, agribusiness, logistics and real estate development. Headquartered in India, Mahindra employs over 2, 56,000 people across 100 countries.
Connect with us on www.techmahindra.com
Our Social Media Channels
Facebook: https://www.facebook.com/TechMahindra
Twitter: https://twitter.com/Tech_Mahindra
LinkedIn: https://www.linkedin.com/company/tech-mahindra/
YouTube: https://www.youtube.com/user/techmahindra09
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005512/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom